List of SBIR/STTR awards granted to Mapp Biopharmaceutical Inc
Mapp Biopharmaceutical IncName | Description | SBIR/STTR Award Recipient | Government Agency | Government Branch | Award Type | Contract Number (US Government) | Award Phase | Award Amount (USD) | Date Awarded | Official Website | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in June, 2018 for $298,015.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R44AI141282-01 | Phase I | 298,015 | June 29, 2018 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc in July, 2020 for $998,825.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 2R44AI136272-03 | Phase II | 998,825 | July 2, 2020 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in January, 2018 for $600,000.0 USD from the U.S. Department of Health & Human Services and National Institutes of Health. | SBIR | 1R43AI136272-01 | Phase I | 600,000 | January 15, 2018 | |||||||
A STTR Phase II contract was awarded to Mapp Biopharmaceutical Inc in July, 2020 for $999,034.0 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. | STTR | W911-QY-20-C-0099 | Phase II | 999,034 | July 28, 2020 | |||||||
A STTR Phase I contract was awarded to Mapp Biopharmaceutical Inc in September, 2018 for $149,998.71 USD from the U.S. Department of Defense and Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense. | STTR | W911QY-18-P-0299 | Phase I | 149,998.71 | September 27, 2018 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in February, 2017 for $255,046.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI129082-01 | Phase I | 255,046 | February 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc in June, 2017 for $999,927.74 USD from the U.S. Department of Defense. | SBIR | W911QY-16-C-0051 | Phase II | 999,927.74 | June 22, 2017 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in August, 2016 for $240,221.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI126968-01 | Phase I | 240,221 | August 1, 2016 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in January, 2015 for $228,758.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI115840-01 | Phase I | 228,758 | January 5, 2015 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc in July, 2017 for $3,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2SB1AI082744-06A1 | Phase II | 3,000,000 | July 1, 2017 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc in July, 2014 for $2,999,994.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI082744-03 | Phase II | 2,999,994 | July 1, 2014 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc in August, 2014 for $2,306,794.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI081392-03A1 | Phase II | 2,306,794 | August 20, 2014 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in July, 2014 for $600,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI114069-01 | Phase I | 600,000 | July 1, 2014 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in September, 2017 for $225,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43IP001085-01 | Phase I | 225,000 | September 1, 2017 | |||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc in December, 2014 for $149,876.77 USD from the U.S. Department of Defense. | SBIR | W911QY-14-P-0232 | Phase I | 149,876.77 | December 11, 2014 | |||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc for $2,815,180.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AG025641-03 | Phase II | 2,815,180 | ||||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc for $3,000,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI072915-03 | Phase II | 3,000,000 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $600,000.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI091078-01 | Phase I | 600,000 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $599,821.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI081392-01 | Phase I | 599,821 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $224,988.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43CA186591-01A1 | Phase I | 224,988 | ||||||||
A SBIR Phase II contract was awarded to Mapp Biopharmaceutical Inc for $997,007.0 USD from the U.S. Department of Health & Human Services. | SBIR | 2R44AI058345-02 | Phase II | 997,007 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $270,810.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI072915-01 | Phase I | 270,810 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $299,986.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI102395-01 | Phase I | 299,986 | ||||||||
A SBIR Phase I contract was awarded to Mapp Biopharmaceutical Inc for $524,876.0 USD from the U.S. Department of Health & Human Services. | SBIR | 1R43AI082744-01 | Phase I | 524,876 |
